Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

Robert J. Ferrante, Hoon Ryu, James K. Kubilus, Santosh D'Mello, Katharine L. Sugars, Junghee Lee, Peiyuan Lu, Karen Smith, Susan Browne, M. Flint Beal, Bruce S. Kristal, Irina G. Stavrovskaya, Sandra Hewett, David C. Rubinsztein, Brett Langley, Rajiv R. Ratan

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Huntington's disease (HD) is a fully penetrant autosomal-dominant inherited neurological disorder caused by expanded CAG repeats in the Huntingtin gene. Transcriptional dysfunction, excitotoxicity, and oxidative stress have all been proposed to play important roles in the pathogenesis of HD. This study was designed to explore the therapeutic potential of mithramycin, a clinically approved guanosine-cytosine-rich DNA binding antitumor antibiotic. Pharmacological treatment of a transgenic mouse model of HD (R6/2) with mithramycin extended survival by 29.1%, greater than any single agent reported to date. Increased survival was accompanied by improved motor performance and markedly delayed neuropathological sequelae. To identify the functional mechanism for the salubrious effects of mithramycin, we examined transcriptional dysfunction in R6/2 mice. Consistent with transcriptional repression playing a role in the pathogenesis of HD, we found increased methylation of lysine 9 in histone H3, a well established mechanism of gene silencing. Mithramycin treatment prevented the increase in H3 methylation observed in R6/2 mice, suggesting that the enhanced survival and neuroprotection might be attributable to the alleviation of repressed gene expression vital to neuronal function and survival. Because it is Food and Drug Administration-approved, mithramycin is a promising drug for the treatment of HD.

Original languageEnglish (US)
Pages (from-to)10335-10342
Number of pages8
JournalJournal of Neuroscience
Volume24
Issue number46
DOIs
StatePublished - Nov 17 2004
Externally publishedYes

Fingerprint

Plicamycin
Huntington Disease
Anti-Bacterial Agents
Drug Therapy
Brain
Methylation
Guanosine
Cytosine
Gene Silencing
United States Food and Drug Administration
Therapeutics
Nervous System Diseases
Histones
Transgenic Mice
Lysine
Oxidative Stress
Pharmacology
Gene Expression
DNA
Pharmaceutical Preparations

Keywords

  • HD
  • Histone methylation
  • Htt
  • Huntingtin
  • Huntington's disease
  • Mithramycin
  • Neuroprotection
  • Transcription

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Ferrante, R. J., Ryu, H., Kubilus, J. K., D'Mello, S., Sugars, K. L., Lee, J., ... Ratan, R. R. (2004). Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. Journal of Neuroscience, 24(46), 10335-10342. https://doi.org/10.1523/JNEUROSCI.2599-04.2004

Chemotherapy for the brain : The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. / Ferrante, Robert J.; Ryu, Hoon; Kubilus, James K.; D'Mello, Santosh; Sugars, Katharine L.; Lee, Junghee; Lu, Peiyuan; Smith, Karen; Browne, Susan; Beal, M. Flint; Kristal, Bruce S.; Stavrovskaya, Irina G.; Hewett, Sandra; Rubinsztein, David C.; Langley, Brett; Ratan, Rajiv R.

In: Journal of Neuroscience, Vol. 24, No. 46, 17.11.2004, p. 10335-10342.

Research output: Contribution to journalArticle

Ferrante, RJ, Ryu, H, Kubilus, JK, D'Mello, S, Sugars, KL, Lee, J, Lu, P, Smith, K, Browne, S, Beal, MF, Kristal, BS, Stavrovskaya, IG, Hewett, S, Rubinsztein, DC, Langley, B & Ratan, RR 2004, 'Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease', Journal of Neuroscience, vol. 24, no. 46, pp. 10335-10342. https://doi.org/10.1523/JNEUROSCI.2599-04.2004
Ferrante, Robert J. ; Ryu, Hoon ; Kubilus, James K. ; D'Mello, Santosh ; Sugars, Katharine L. ; Lee, Junghee ; Lu, Peiyuan ; Smith, Karen ; Browne, Susan ; Beal, M. Flint ; Kristal, Bruce S. ; Stavrovskaya, Irina G. ; Hewett, Sandra ; Rubinsztein, David C. ; Langley, Brett ; Ratan, Rajiv R. / Chemotherapy for the brain : The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. In: Journal of Neuroscience. 2004 ; Vol. 24, No. 46. pp. 10335-10342.
@article{48f4e166d76044c38608f8d8aee702e7,
title = "Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease",
abstract = "Huntington's disease (HD) is a fully penetrant autosomal-dominant inherited neurological disorder caused by expanded CAG repeats in the Huntingtin gene. Transcriptional dysfunction, excitotoxicity, and oxidative stress have all been proposed to play important roles in the pathogenesis of HD. This study was designed to explore the therapeutic potential of mithramycin, a clinically approved guanosine-cytosine-rich DNA binding antitumor antibiotic. Pharmacological treatment of a transgenic mouse model of HD (R6/2) with mithramycin extended survival by 29.1{\%}, greater than any single agent reported to date. Increased survival was accompanied by improved motor performance and markedly delayed neuropathological sequelae. To identify the functional mechanism for the salubrious effects of mithramycin, we examined transcriptional dysfunction in R6/2 mice. Consistent with transcriptional repression playing a role in the pathogenesis of HD, we found increased methylation of lysine 9 in histone H3, a well established mechanism of gene silencing. Mithramycin treatment prevented the increase in H3 methylation observed in R6/2 mice, suggesting that the enhanced survival and neuroprotection might be attributable to the alleviation of repressed gene expression vital to neuronal function and survival. Because it is Food and Drug Administration-approved, mithramycin is a promising drug for the treatment of HD.",
keywords = "HD, Histone methylation, Htt, Huntingtin, Huntington's disease, Mithramycin, Neuroprotection, Transcription",
author = "Ferrante, {Robert J.} and Hoon Ryu and Kubilus, {James K.} and Santosh D'Mello and Sugars, {Katharine L.} and Junghee Lee and Peiyuan Lu and Karen Smith and Susan Browne and Beal, {M. Flint} and Kristal, {Bruce S.} and Stavrovskaya, {Irina G.} and Sandra Hewett and Rubinsztein, {David C.} and Brett Langley and Ratan, {Rajiv R.}",
year = "2004",
month = "11",
day = "17",
doi = "10.1523/JNEUROSCI.2599-04.2004",
language = "English (US)",
volume = "24",
pages = "10335--10342",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "46",

}

TY - JOUR

T1 - Chemotherapy for the brain

T2 - The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

AU - Ferrante, Robert J.

AU - Ryu, Hoon

AU - Kubilus, James K.

AU - D'Mello, Santosh

AU - Sugars, Katharine L.

AU - Lee, Junghee

AU - Lu, Peiyuan

AU - Smith, Karen

AU - Browne, Susan

AU - Beal, M. Flint

AU - Kristal, Bruce S.

AU - Stavrovskaya, Irina G.

AU - Hewett, Sandra

AU - Rubinsztein, David C.

AU - Langley, Brett

AU - Ratan, Rajiv R.

PY - 2004/11/17

Y1 - 2004/11/17

N2 - Huntington's disease (HD) is a fully penetrant autosomal-dominant inherited neurological disorder caused by expanded CAG repeats in the Huntingtin gene. Transcriptional dysfunction, excitotoxicity, and oxidative stress have all been proposed to play important roles in the pathogenesis of HD. This study was designed to explore the therapeutic potential of mithramycin, a clinically approved guanosine-cytosine-rich DNA binding antitumor antibiotic. Pharmacological treatment of a transgenic mouse model of HD (R6/2) with mithramycin extended survival by 29.1%, greater than any single agent reported to date. Increased survival was accompanied by improved motor performance and markedly delayed neuropathological sequelae. To identify the functional mechanism for the salubrious effects of mithramycin, we examined transcriptional dysfunction in R6/2 mice. Consistent with transcriptional repression playing a role in the pathogenesis of HD, we found increased methylation of lysine 9 in histone H3, a well established mechanism of gene silencing. Mithramycin treatment prevented the increase in H3 methylation observed in R6/2 mice, suggesting that the enhanced survival and neuroprotection might be attributable to the alleviation of repressed gene expression vital to neuronal function and survival. Because it is Food and Drug Administration-approved, mithramycin is a promising drug for the treatment of HD.

AB - Huntington's disease (HD) is a fully penetrant autosomal-dominant inherited neurological disorder caused by expanded CAG repeats in the Huntingtin gene. Transcriptional dysfunction, excitotoxicity, and oxidative stress have all been proposed to play important roles in the pathogenesis of HD. This study was designed to explore the therapeutic potential of mithramycin, a clinically approved guanosine-cytosine-rich DNA binding antitumor antibiotic. Pharmacological treatment of a transgenic mouse model of HD (R6/2) with mithramycin extended survival by 29.1%, greater than any single agent reported to date. Increased survival was accompanied by improved motor performance and markedly delayed neuropathological sequelae. To identify the functional mechanism for the salubrious effects of mithramycin, we examined transcriptional dysfunction in R6/2 mice. Consistent with transcriptional repression playing a role in the pathogenesis of HD, we found increased methylation of lysine 9 in histone H3, a well established mechanism of gene silencing. Mithramycin treatment prevented the increase in H3 methylation observed in R6/2 mice, suggesting that the enhanced survival and neuroprotection might be attributable to the alleviation of repressed gene expression vital to neuronal function and survival. Because it is Food and Drug Administration-approved, mithramycin is a promising drug for the treatment of HD.

KW - HD

KW - Histone methylation

KW - Htt

KW - Huntingtin

KW - Huntington's disease

KW - Mithramycin

KW - Neuroprotection

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=20844455450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844455450&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.2599-04.2004

DO - 10.1523/JNEUROSCI.2599-04.2004

M3 - Article

C2 - 15548647

AN - SCOPUS:20844455450

VL - 24

SP - 10335

EP - 10342

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 46

ER -